End-of-day quote
LUXEMBOURG S.E.
18:00:00 2024-06-17 EDT
|
5-day change
|
1st Jan Change
|
25.4
USD
|
+1.60%
|
|
+1.60%
|
+0.79%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,193,129
|
1,381,559
|
1,619,625
|
1,542,290
|
1,627,029
|
1,694,305
|
-
|
-
|
Enterprise Value (EV)
1 |
1,062,663
|
1,239,491
|
1,559,769
|
1,395,557
|
1,546,536
|
1,567,013
|
1,499,404
|
1,344,409
|
P/E ratio
|
24.2
x
|
13.2
x
|
11.6
x
|
9.94
x
|
10.2
x
|
7.07
x
|
6.45
x
|
5.52
x
|
Yield
|
0.98%
|
3.02%
|
2.58%
|
4.7%
|
-
|
5.99%
|
6.35%
|
7.51%
|
Capitalization / Revenue
|
2.35
x
|
2.44
x
|
2.57
x
|
1.92
x
|
2.02
x
|
2.05
x
|
1.85
x
|
1.68
x
|
EV / Revenue
|
2.09
x
|
2.19
x
|
2.47
x
|
1.74
x
|
1.92
x
|
1.89
x
|
1.64
x
|
1.33
x
|
EV / EBITDA
|
9.53
x
|
8.19
x
|
8.86
x
|
7.1
x
|
6.43
x
|
4.83
x
|
3.99
x
|
3.29
x
|
EV / FCF
|
26.1
x
|
18.3
x
|
-460
x
|
12.3
x
|
17.9
x
|
9.82
x
|
7.9
x
|
6.18
x
|
FCF Yield
|
3.83%
|
5.47%
|
-0.22%
|
8.12%
|
5.6%
|
10.2%
|
12.7%
|
16.2%
|
Price to Book
|
1.66
x
|
1.72
x
|
1.78
x
|
1.47
x
|
-
|
1.35
x
|
1.25
x
|
1.08
x
|
Nbr of stocks (in thousands)
|
185,991
|
185,693
|
185,630
|
185,818
|
185,946
|
182,773
|
-
|
-
|
Reference price
2 |
6,415
|
7,440
|
8,725
|
8,300
|
8,750
|
9,325
|
9,325
|
9,325
|
Announcement Date
|
2/7/20
|
2/26/21
|
3/2/22
|
2/28/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
507,794
|
566,776
|
630,595
|
802,755
|
805,158
|
826,995
|
914,452
|
1,007,751
|
EBITDA
1 |
111,534
|
151,330
|
176,123
|
196,480
|
240,625
|
324,590
|
375,410
|
408,962
|
EBIT
1 |
71,863
|
111,484
|
135,832
|
153,555
|
189,817
|
263,627
|
303,741
|
336,979
|
Operating Margin
|
14.15%
|
19.67%
|
21.54%
|
19.13%
|
23.58%
|
31.88%
|
33.22%
|
33.44%
|
Earnings before Tax (EBT)
1 |
51,697
|
115,164
|
146,575
|
165,663
|
171,540
|
299,279
|
319,072
|
379,742
|
Net income
1 |
49,299
|
104,683
|
139,626
|
155,581
|
158,850
|
242,144
|
268,837
|
323,776
|
Net margin
|
9.71%
|
18.47%
|
22.14%
|
19.38%
|
19.73%
|
29.28%
|
29.4%
|
32.13%
|
EPS
2 |
265.0
|
563.0
|
751.0
|
835.0
|
860.0
|
1,320
|
1,447
|
1,691
|
Free Cash Flow
1 |
40,688
|
67,757
|
-3,393
|
113,348
|
86,554
|
159,535
|
189,741
|
217,468
|
FCF margin
|
8.01%
|
11.95%
|
-0.54%
|
14.12%
|
10.75%
|
19.29%
|
20.75%
|
21.58%
|
FCF Conversion (EBITDA)
|
36.48%
|
44.77%
|
-
|
57.69%
|
35.97%
|
49.15%
|
50.54%
|
53.18%
|
FCF Conversion (Net income)
|
82.53%
|
64.73%
|
-
|
72.85%
|
54.49%
|
65.88%
|
70.58%
|
67.17%
|
Dividend per Share
2 |
63.00
|
225.0
|
225.0
|
390.0
|
-
|
558.7
|
592.5
|
699.9
|
Announcement Date
|
2/7/20
|
2/26/21
|
3/2/22
|
2/28/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2021 S1
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
---|
Net sales
1 |
278,692
|
296,803
|
157,518
|
176,274
|
168,057
|
192,923
|
217,807
|
223,968
|
209,653
|
203,783
|
413,436
|
188,544
|
203,178
|
203,432
|
EBITDA
1 |
75,796
|
80,719
|
42,943
|
52,461
|
-
|
64,033
|
77,353
|
11,597
|
65,277
|
52,831
|
118,108
|
61,657
|
59,078
|
75,175
|
EBIT
1 |
55,935
|
60,800
|
33,134
|
41,898
|
-
|
51,972
|
64,840
|
-740
|
54,131
|
40,882
|
95,013
|
49,398
|
44,974
|
63,607
|
Operating Margin
|
20.07%
|
20.48%
|
21.04%
|
23.77%
|
-
|
26.94%
|
29.77%
|
-0.33%
|
25.82%
|
20.06%
|
22.98%
|
26.2%
|
22.14%
|
31.27%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
48,416
|
-
|
-
|
87,457
|
-43,741
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
60,531
|
54,915
|
-
|
46,518
|
37,906
|
76,532
|
82,417
|
-40,422
|
39,036
|
28,743
|
67,936
|
-
|
-
|
68,217
|
Net margin
|
21.72%
|
18.5%
|
-
|
26.39%
|
22.56%
|
39.67%
|
37.84%
|
-18.05%
|
18.62%
|
14.1%
|
16.43%
|
-
|
-
|
33.53%
|
EPS
|
-
|
-
|
-
|
250.0
|
-
|
411.0
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/3/20
|
8/3/21
|
11/8/21
|
3/2/22
|
5/9/22
|
8/3/22
|
11/7/22
|
2/28/23
|
5/12/23
|
8/4/23
|
8/4/23
|
11/8/23
|
2/29/24
|
5/14/24
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
130,466
|
142,068
|
59,856
|
146,733
|
80,493
|
127,291
|
194,900
|
349,896
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
40,688
|
67,757
|
-3,393
|
113,348
|
86,554
|
159,535
|
189,741
|
217,468
|
ROE (net income / shareholders' equity)
|
9.7%
|
13.7%
|
16.2%
|
15.8%
|
14.5%
|
17.7%
|
18.4%
|
19.4%
|
ROA (Net income/ Total Assets)
|
9.7%
|
11.6%
|
13.3%
|
-
|
11.7%
|
17%
|
18%
|
18%
|
Assets
1 |
508,169
|
903,624
|
1,046,939
|
-
|
1,357,495
|
1,424,379
|
1,493,536
|
1,798,754
|
Book Value Per Share
2 |
3,874
|
4,333
|
4,910
|
5,633
|
-
|
6,922
|
7,486
|
8,647
|
Cash Flow per Share
2 |
528.0
|
723.0
|
752.0
|
992.0
|
670.0
|
1,556
|
1,458
|
1,661
|
Capex
1 |
57,552
|
66,638
|
143,297
|
71,579
|
94,639
|
93,350
|
88,152
|
93,702
|
Capex / Sales
|
11.33%
|
11.76%
|
22.72%
|
8.92%
|
11.75%
|
11.29%
|
9.64%
|
9.3%
|
Announcement Date
|
2/7/20
|
2/26/21
|
3/2/22
|
2/28/23
|
2/29/24
|
-
|
-
|
-
|
Last Close Price
9,325
HUF Average target price
11,800
HUF Spread / Average Target +26.55% Consensus |
1st Jan change
|
Capi.
|
---|
| +19.42% | 43.78B | | +18.87% | 21.56B | | +21.10% | 15.64B | | +25.15% | 15.25B | | +55.77% | 13.02B | | -0.05% | 6.79B | | -15.94% | 6.36B | | +16.15% | 5.81B | | -8.87% | 5.73B |
Generic Pharmaceuticals
|